NGGT003
/ NGGT (Suzhou) Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 21, 2025
Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
(clinicaltrials.gov)
- P1 | N=6 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases
1 to 1
Of
1
Go to page
1